PL3920970T3 - Sposób leczenia zdarzeń niepożądanych indukowanych przez inhibitory punktów kontrolnych - Google Patents

Sposób leczenia zdarzeń niepożądanych indukowanych przez inhibitory punktów kontrolnych

Info

Publication number
PL3920970T3
PL3920970T3 PL20702304.5T PL20702304T PL3920970T3 PL 3920970 T3 PL3920970 T3 PL 3920970T3 PL 20702304 T PL20702304 T PL 20702304T PL 3920970 T3 PL3920970 T3 PL 3920970T3
Authority
PL
Poland
Prior art keywords
treating
adverse events
checkpoint inhibitors
induced adverse
inhibitors induced
Prior art date
Application number
PL20702304.5T
Other languages
English (en)
Inventor
Joe-Elie SALEM
Yves Allenbach
Mathieu KERNEIS
Javid MOSLEHI
Douglas Johnson
Original Assignee
Assistance Publique Hôpitaux De Paris
Sorbonne Université
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3920970(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Assistance Publique Hôpitaux De Paris, Sorbonne Université, Institut National De La Santé Et De La Recherche Médicale (Inserm), Vanderbilt University filed Critical Assistance Publique Hôpitaux De Paris
Publication of PL3920970T3 publication Critical patent/PL3920970T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20702304.5T 2019-02-04 2020-02-03 Sposób leczenia zdarzeń niepożądanych indukowanych przez inhibitory punktów kontrolnych PL3920970T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305128 2019-02-04
PCT/EP2020/052554 WO2020161045A1 (en) 2019-02-04 2020-02-03 Method for treating checkpoint inhibitors induced adverse events

Publications (1)

Publication Number Publication Date
PL3920970T3 true PL3920970T3 (pl) 2023-03-13

Family

ID=65494072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20702304.5T PL3920970T3 (pl) 2019-02-04 2020-02-03 Sposób leczenia zdarzeń niepożądanych indukowanych przez inhibitory punktów kontrolnych

Country Status (9)

Country Link
US (1) US20220125880A1 (pl)
EP (1) EP3920970B1 (pl)
CA (1) CA3128425A1 (pl)
DK (1) DK3920970T3 (pl)
ES (1) ES2935265T3 (pl)
FI (1) FI3920970T3 (pl)
PL (1) PL3920970T3 (pl)
PT (1) PT3920970T (pl)
WO (1) WO2020161045A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125880A1 (en) 2019-02-04 2022-04-28 Assistance Publique - Hôpitaux De Paris Method for treating checkpoint inhibitors induced adverse events
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2762015A1 (en) 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
EP3515489A4 (en) 2016-09-19 2020-05-06 Oncoimmune, Inc. CD80 AND CD86 BINDING PROTEIN COMPOSITIONS AND USES THEREOF
US20220125880A1 (en) 2019-02-04 2022-04-28 Assistance Publique - Hôpitaux De Paris Method for treating checkpoint inhibitors induced adverse events

Also Published As

Publication number Publication date
EP3920970B1 (en) 2022-11-23
WO2020161045A1 (en) 2020-08-13
US20220125880A1 (en) 2022-04-28
EP3920970A1 (en) 2021-12-15
DK3920970T3 (da) 2023-01-23
FI3920970T3 (fi) 2023-01-31
PT3920970T (pt) 2023-01-05
ES2935265T3 (es) 2023-03-03
CA3128425A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
IL285496A (en) Methods for treating biliary obstruction
GB202201846D0 (en) Method for selecting pollutant treatment measure
PL3733308T3 (pl) Sposób i urządzenie do obróbki powierzchni
EP3742125C0 (en) METHOD AND SYSTEM FOR PATH PLANNING
EP3934421C0 (de) Vorrichtung zur behandlung eines bodens und verfahren zum betreiben einer derartigen vorrichtung
IL280128A (en) A method for treating epilepsy
PL3768622T3 (pl) Maszyna do pozycjonowania przedmiotów i sposób pozycjonowania przedmiotów
EP3870760C0 (de) Verfahren und gleisbaumaschine zum stabilisieren eines gleises
FI3920970T3 (fi) Menetelmä tarkistuspisteen estäjien aiheuttamien haittatapahtumien hoitamiseksi
IL283665A (en) Methods for treating or preventing rheumatism or hyperuricemia
PL3543405T3 (pl) Sposób i urządzenie do obróbki gleby
SG11202106014QA (en) A method for treating lipid materials
EP4143204A4 (en) METHODS FOR TREATING COVID-19
HUE052103T2 (hu) Melegen hengerelt acél és eljárás melegen hengerelt acél elõállítására
IL287865A (en) Pde9 inhibitors for treating thalassemia
IL280800A (en) A method for treating pancreatic cancer
GB201900789D0 (en) Method for testing time distribution
PL3522053T3 (pl) Sposób uwierzytelniania twarzy
IL279425A (en) System and method for reuse in split wash
GB201909228D0 (en) Screen for inhibitors
PL3718692T3 (pl) Urządzenie i sposób obróbki końcowej elementów konstrukcyjnych
GB201814181D0 (en) Method of treating a substrate
SG11202111877TA (en) Method for treating cough by using diaminopyrimidine compound
DE112020002433A5 (de) Vorrichtung zum sichern und/oder befestigen, verwendung und verfahren
SG11202111960PA (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound